Innate Pharma S.A.
IPHYFOTCHealthcare● Active
$2.25
+$0.60(+36.36%)
Market Cap$211282398
P/E Ratio—
52W High$2.25
52W Low$1.31
Innate Pharma S.A. (IPHYF) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · IPHYF · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $2.79M | $12.62M | $61.64M | $49.64M | $12.11M |
| Cost of Revenue | $0.00M | $0.00M | $56.02M | $51.66M | $47.00M |
| Gross Profit | $2.79M | $12.62M | $5.62M | $6.01M | ($22.30M) |
| Gross Margin %(computed) | 100.04% | 100.00% | 9.12% | 12.11% | -184.12% |
| Operating Expenses | |||||
| R&D Expenses | $43.60M | $51.98M | $56.02M | $51.66M | $47.00M |
| G&A Expenses | $11.00M | $11.93M | $17.97M | $14.47M | $15.99M |
| Total Operating Expenses | $56.21M | $64.20M | $18.29M | $63.44M | $25.52M |
| Operating Income | ($53.42M) | ($51.58M) | ($12.67M) | ($57.42M) | ($47.83M) |
| Operating Margin %(computed) | — | -408.64% | -20.55% | -115.69% | -394.86% |
| Interest Income | $7.95M | $2.44M | $3.18M | $0.55M | $0.33M |
| Interest Expense | $3.12M | $0.57M | $0.64M | $0.29M | $0.31M |
| Income Before Tax | ($49.18M) | ($49.47M) | ($7.57M) | ($57.97M) | ($45.48M) |
| Income Tax Expense | ($6.20M) | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($49.16M) | ($49.47M) | ($7.57M) | ($58.10M) | ($52.81M) |
| Net Margin %(computed) | — | -391.97% | -12.28% | -117.05% | -436.01% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.55 | $-0.61 | $-0.09 | $-0.73 | $-0.57 |
| Wtd Avg Shares | 89.41M | 81.05M | 84.11M | 79.59M | 79.54M |
| EBITDA | ($43.65M) | ($46.91M) | ($7.58M) | ($12.28M) | ($43.23M) |
| EBITDA Margin %(computed) | — | -371.69% | -12.29% | -24.74% | -356.91% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · EUR · M
Explore more Innate Pharma S.A. data
About Innate Pharma S.A. (IPHYF) Income Statement
Innate Pharma S.A. (IPHYF) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, IPHYF reported revenue of $0.00B, gross profit of $0.00B (gross margin 100.04%), and net income of ($0.05B) — a net profit margin of -1764.51%.
Frequently asked questions
IPHYF · 4 questionsInnate Pharma S.A. (IPHYF) reported revenue of $0.00B for 2025, down 77.9% year-over-year.
IPHYF revenueIPHYF salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09